Entyvio Dosage & Drug Information

Concise Prescribing Info

Contents

Vedolizumab

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Indications/Uses

Adult patients w/ moderately or severely active ulcerative colitis or Crohn's disease who have had inadequate response w/, lost response to or were intolerant to either conventional therapy or tumour necrosis factor-α antagonist.

Dosage/Direction for Use

Ulcerative colitis & Crohn's disease SC 108 mg once every 2 wk followed by 1st SC maintenance dose to be administered in place of next scheduled IV dose & every 2 wk thereafter. IV 300 mg infusion at 0, 2 & 6 wk then every 8 wk thereafter.

Contraindications

Hypersensitivity. Active severe infections [eg, TB, sepsis, cytomegalovirus, listeriosis & opportunistic infections (eg, PML)].

MIMS Class

GIT Regulators, Antiflatulents & Anti-Inflammatories / Immunosuppressants

ATC Classification

L04AG05 - vedolizumab ; Belongs to the class of monoclonal antibodies. Used as immunosuppressants.

Regulatory Classification

POM

Presentation/Packing

Form

Entyvio powd for conc for soln for infusion 300 mg

Packing/Price

1's

Form

Entyvio soln for inj 108 mg/0.68 mL

Packing/Price

1's

Entyvio

vedolizumab

Manufacturer:

Takeda